|
Use of Immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis |
Apr 2019 |
Haemotologica |
Myelodysplastic Syndromes (MDS) |
|
Flaming and fanning: The Spectrum of inflammatory influences in myelodysplastic syndromes |
Apr 2019 |
Blood Reviews |
Myelodysplastic Syndromes (MDS) |
|
Eltrombopag for refractory severe aplastic anemia: dosing, duration, long term outcomes and clonal evolution |
Apr 2019 |
Blood |
Aplastic Anemia |
|
Getting personal with myelodysplastic syndromes: is now the right time? |
Apr 2019 |
Expert Review of Hematology |
Myelodysplastic Syndromes (MDS) |
|
Immunosuppressive therapy for pediatric aplastic anemia: a North American Pediatric Aplastic Anemia Consortium study |
Apr 2019 |
Haematologica |
Aplastic Anemia |
|
A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS) |
Mar 2019 |
Leukemia Research |
Myelodysplastic Syndromes (MDS) |
|
Myelodysplastic Syndromes Treatment (PDQ®): Patient Version |
Mar 2019 |
National Cancer Institute |
Myelodysplastic Syndromes (MDS) |
|
Clonal Hematopoiesis and therapy related MDS/AML |
Mar 2019 |
Best Practice & Research. Clinical Heamatology |
Myelodysplastic Syndromes (MDS) |
|
Significant hemolysis is not required for thrombosis in paroxysmal nocturnal hemoglobinuria. |
Mar 2019 |
Haematologica |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic Syndromes |
Mar 2019 |
Clin Lymphoma Myeloma Leuk |
Myelodysplastic Syndromes (MDS) |
